Anti T-lymphocyte globulin - Neovii Biotech
Alternative Names: Anti-T-lymphocyte immune globulin; Antithymocyte globulin - Fresenius; Antithymocyte immunoglobulin (rabbit) - Neovii Biotech; ATG S Fresenius; ATG-Fresenius-S; ENZN-2053; EZ-2053; Grafalon; US-ATG-FLatest Information Update: 27 Jan 2022
At a glance
- Originator Fresenius Biotech
- Developer Neovii Biotech
- Class Polyclonal antibodies
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Graft-versus-host disease; Renal transplant rejection; Transplant rejection
- Discontinued Lung transplant rejection
Most Recent Events
- 11 Dec 2021 Interim efficacy data from phase II MDS-ALLO-Risk trial in Graft versus host disease presented at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2021)
- 19 Feb 2021 Phase-III development is ongoing in the US (Neovii Biotech pipeline, February 2021 )
- 19 Feb 2021 Discontinued - Phase-III for Graft-versus-host disease (Prevention) in Australia (IV) (Neovii Biotech pipeline, February 2021).